Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants

Britto, Renata Lopes; Araújo, Leila Maria Batista; Barbosa, Ione Cristina; Silva, Lidia

doi:10.3109/09513590.2012.664191

Cited by 8 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies in post-menopausal women have also reported an inverse relation between endogenous androgen levels, dyslipidemia and atherosclerosis (Bernini et al, 2001;Khatibi et al, 2007;Ouyang et al, 2009). Furthermore, improvements in lipid profiles following estradiol/testosterone replacement therapy have been reported in post-menopausal women (Castelo-Branco et al, 2007;Britto et al, 2012).…”

Section: Introductionmentioning

confidence: 97%

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

et al. 2015

View full text Add to dashboard Cite

N.M.P.D. is supported by the Dutch Heart Foundation (grant number 2013T083). L.J. and O.H.F. work in ErasmusAGE, a center for aging research across the life course, funded by Nestlé Nutrition (Nestec Ltd), Metagenics Inc. and AXA. M.K. is supported by the AXA Research Fund. Nestlé Nutrition (Nestec Ltd), Metagenics Inc. and AXA had no role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript. J.S.E.L. has received fees and grant support from the following companies (in alphabetical order): Ferring, Merck-Serono, Merck Sharpe & Dome, Organon, Schering Plough and Serono. In the last 5 years, B.C.J.M.F. has received fees and grant support from the following companies (in alphabetic order); Actavis, COGI, Euroscreen, Ferring, Finox, Genovum, Gedeon-Richter, Merck-Serono, OvaScience, Pantharei Bioscience, PregLem, Roche, Uteron and Watson laboratories. With regard to potential conflicts of interest, there is nothing further to disclose.

show abstract

Section: Introductionmentioning

confidence: 97%

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The studies carried out in postmenopausal women have reported an inverse relation between estrogen levels, dyslipidemia, and atherosclerosis (21,22). The improvements in lipid profile following hormonal replacement therapy have been established in postmenopausal women (23). Lipid status was evaluated among the subjects.…”

Section: Discussionmentioning

confidence: 99%

Subclinical Hypothyroidism is Associated with Atherogenic Lipid Profile in Postmenopausal Women

Godinjak¹,

Velija-Ašimi²,

Bureković³

et al. 2017

Turk J Endocrinol Metab

View full text Add to dashboard Cite

IntroductionSubclinical hypothyroidism (SH) is defined as an elevated serum level of thyroid stimulating hormone (TSH) with the normal levels of free thyroxine (FT4) and free triiodothyronine (FT3) (1). Most patients are symptomless and have serum TSH levels <10 mU/L. In the studies conducted on the general population, the prevalence of subclinical hypothyroidism ranges from 4% to 15% (2). The preva-37 S Su ub bc cl li in ni ic ca al l H Hy yp po ot th hy yr ro oi id di is sm m i is s A As ss so oc ci ia at te ed d w wi it th h A At th he er ro og ge en ni ic c L Li ip pi id d P Pr ro ofi fil le e i in n P Po os st tm me en no op pa au us sa al l W Wo om me en n Purpose: To determine the prevalence and association of atherogenic lipid profile in postmenopausal women with subclinical hypothyroidism. Materials (Subjects) and Methods: This as a prospective clinical study included 140 postmenopausal women. In all subjects, basic sociodemographic and anthropometric data, hormonal status of the thyroid gland, and lipid profile were determined. The subjects were followed for a period of 30 months.Results: The subclinical hypothyroidism in postmenopausal women was significantly associated with higher levels of serum cholesterol, triglycerides, LDL-C, and lower HDL-C (p=0.009, p=0.01, p=0.023, p=0.001, respectively). Furthermore, the analysis of repeated measures showed that subclinical hypothyroidism, irrespective of age and duration of postmenopause, was associated with higher levels of serum cholesterol (

show abstract

“…Higher doses of T have been shown to correlate with a more significant improvement in quality of life. In addition, previous studies have not confirmed side effects such as deepening of the voice [81] and worsening of cholesterol [82]. There is an improvement in symptoms with T implants as evidenced by the 'Menopause Rating Scale' total score, including symptom reduction and improvement in psychological and urogenital complaints [1].…”

Section: The Benefits and Effectiveness Of T Implant Therapymentioning

confidence: 92%

Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?

Renke

Tostes

2023

Pharmaceuticals

View full text Add to dashboard Cite

We discuss the CV safety and efficacy data for subcutaneous testosterone therapy (STT) in postmenopausal women. We also highlight new directions and applications of correct dosages performed in a specialized center. To recommend STT, we propose innovative criteria (IDEALSTT) according to total testosterone (T) level, carotid artery intima-media thickness, and calculated SCORE for a 10-year risk of fatal cardiovascular disease (CVD). Despite all the controversies, hormone replacement therapy (HRT) with T has gained prominence in treating pre and postmenopausal women in the last decades. HRT with silastic and bioabsorbable testosterone hormone implants has gained prominence recently due to its practicality and effectiveness in treating menopausal symptoms and hypoactive sexual desire disorder. A recent publication on the complications of STT, looking at a large cohort of patients over seven years, demonstrated its long-term safety. However, the cardiovascular (CV) risk and safety of STT in women are still controversial.

show abstract

Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants

Abstract: The use of E and T implants showed some statistically significant decrease in TC at the beginning of the HT and some decrease in LDL in the group using HT. In the group without HT there was no difference in lipid profile.

Cited by 8 publications

References 32 publications

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

Subclinical Hypothyroidism is Associated with Atherogenic Lipid Profile in Postmenopausal Women

Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?

Contact Info

Product

Resources

About